Author:
Hanczuk Tatjana,Weiss Martin,Henes Leon,Engler Tobias,Neis Felix,Henes Melanie
Abstract
Abstract
Purpose
This study evaluates the overall treatment indicators and outcomes of patients who underwent loop electrosurgical excision procedure (LEEP) at the Department of Women’s Health Tübingen and the impact of certification as a dysplasia unit on treatment quality.
Methods
Retrospective data analysis of 1596 patients from 2013 to 2018 who underwent LEEP excision at the Department of Women’s Health Tübingen. Data of cytology, colposcopy, biopsy, LEEP histology, repeat LEEP histology and general characteristics were collected and analyzed descriptively.
Results
85.4% (1364) of patients had CIN 2 + and 14.6% (232) had CIN 1 or normal findings on LEEP histology. The proportion of CIN 2 + excisions increased significantly from 82.4% in 2013 to 89% in 2018. The concordance of HSIL biopsy and LEEP histology was 89.1% in 2013 and 92.6% in 2018. In 2018, more biopsies and colposcopies were performed before excision. Complete resection (R0) was achieved in 88.3% of all excisions. R0 rates in patients with CIN 3 increased in 2014–2017 compared to 2013, resulting in fewer Re-LEEP excisions and hysterectomies.
Conclusion
Certification as a dysplasia unit and the associated requirements have improved the diagnostic quality for patients with cervical dysplasia undergoing LEEP. This was demonstrated by several treatment indicators such as the number of colposcopies and biopsies and treatment outcomes such as an increased proportion of CIN 2 + excisions and R0 resections.
Funder
Universitätsklinikum Tübingen
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,General Medicine
Reference33 articles.
1. International Agency for Research on Cancer (2021) Cervix uteri fact sheet: Cancer today. https://gco.iarc.fr/today/fact-sheets-cancers. Accessed 31 Jan 2022
2. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2020) Leitlinienprogramm Onkologie. Prävention des Zervixkarzinoms, Langversion 1.1, AWMF Registernummer: 015/027OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom-praevention/. Accessed 31 Jan 2022
3. Robert Koch-Institut (2020) Impfstatus der Kinder und Jugendlichen in Deutschland: Epidemiologisches Bulletin 32/33. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/32-33_20.pdf?__blob=publicationFile. Accessed 28 Oct 2020
4. Palmer T, Wallace L, Pollock KG et al (2019) Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ 365:l1161. https://doi.org/10.1136/bmj.l1161
5. Crosbie EJ, Einstein MH, Franceschi S et al (2013) Human papillomavirus and cervical cancer. Lancet 382:889–899. https://doi.org/10.1016/S0140-6736(13)60022-7